Mediators of Inflammation, Prognostic Markers and Genetic Polymorphisms in Patients With Sepsis
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 105
- 试验地点
- 2
- 主要终点
- New Prognostic markers for septic patients
研究概览
简要总结
Aims of the study were to find vascular markers of inflammation and endothelial damage during the course of severe sepsis in septic patients and the effects of treatment with anti-inflammatory medication (such as Drotregocin alfa (activated)). Another aim is to find new markers and gene polymorphisms for prognosis and mortality of patients with severe sepsis. The hypothesis is that higher plasma concentrations of certain markers in septic patients are associated with a higher mortality rate.
详细描述
During the past years many investigators have focused on the immunological changes in sepsis disease, and great attention has been paid to the development of practicable means of immunomonitoring. Human activated protein C (Drotrecogin alfa (activated)), an important coagulation inhibitor plays a major role in regulating microvascular coagulation, inflammation and immunology. Little is known about prognostic vascular biomarkers during the time course of patients with severe sepsis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •SIRS-Criteria
- •Proven Infection
- •One sepsis-induced organ-failure
- •Adults <18 years old
排除标准
- •Pregnancy
- •Blood donor in the last 3 month
结局指标
主要结局
New Prognostic markers for septic patients
时间窗: until 300 Patients are included
次要结局
未报告次要终点
研究者
Dr. med. Ursula Hoffmann
PD Dr. med.
Universitätsmedizin Mannheim